Clinical Trials Logo

Clinical Trial Summary

Transverse myelitis is an inflammatory disorder of the spinal cord that leads to disabilities of gait. Dalfampridine, a sustained-release potassium channel blocker that has been shown to be effective in improving gait and other neurologic functions in multiple sclerosis. Dalfampridine has the potential to improve gait and neurologic function in patients with transverse myelitis as this rare disorder shares a similar pathogenic process with multiple sclerosis. The investigators propose a clinical trial to test the efficacy of dalfampridine in this particular cohort of patients.

The clinical trial that the investigators propose to conduct will focus on monophasic idiopathic Transverse Myelitis (TM) and will evaluate the efficacy of dalfampridine in primary neurologic outcome, 25-foot timed walk, and several secondary outcomes including valid behavioral and neurophysiological measures. To better understand the mechanisms underlying the proposed behavioral gains, the investigators will use Transcranial Magnetic Stimulation as the neurophysiologic measure to identify changes in corticomotor excitability in the spinal cord.


Clinical Trial Description

Fampridine (4-aminopyridine) is a potassium channel blocker that has been studied since the 1970s for its effect on amplifying conductivity in demyelinated peripheral nerves, potentiating neurotransmitter release in muscles and increasing post-synaptic action potentials in the spinal cord. It was tested in various human neurologic conditions over the next two decades and was found to have a markedly limited therapeutic window due to the stimulation of seizure activity. Interest in fampridine for treatment of multiple sclerosis (MS) stemmed from small case series of patients who found therapeutic benefit in many different neurologic functions including vision, oculomotor function and motor activity. The first randomized, placebo-controlled, double-blinded study of fampridine in MS in 1992 enrolled 70 patients into a cross over study found significant improvements in a number of neurophysiological parameters while on fampridine that were not seen in patients while on placebo. Since then, at least six additional studies on oral fampridine in MS were conducted and found to have some significant benefits in neurologic function. Although only a small incidence of seizure or altered mental status were reported in these studies, the concern about fampridine causing seizures remained a barrier in the acceptance of fampridine as an MS therapy in the general neurology community.

Recently, Biogen-Idec and Acorda have teamed up in the development of a sustained-release formulation of fampridine, dalfampridine, which maintains stable plasma concentrations of the drug and avoids toxic doses that lead to seizures. In two clinical trials, dalfampridine has been shown to be beneficial in a limited cohort of multiple sclerosis with noted improvements in gait and lower extremity muscle strength. Seizures were only seen in high doses of 30 mg twice daily or more whereas benefits were evident at the now standard dose of 10 mg twice daily.

The Food and Drug Administration (FDA) approved dalfampridine for use in multiple sclerosis in 2009 based on the key study that evaluated the improvement in gait in the responder cohort of patients rather than the entire study population. This method of analysis focused on those who reported some benefit from dalfampridine in an initial 4-week trial period and re-assigned those who did not see benefit to the non-responder group. About 35% of study subjects fell into the responder group and on average, this group improved their walking speed by 25%.

The investigators interest in dalfampridine is focused more narrowly on a subset of patients with a demyelinating disorder that is restricted to the spinal cord. This disorder, transverse myelitis (TM), was not included in any previous human trials of dalfampridine. In contrast to MS, which affects the entire central nervous system, this restricted demyelinating disease affects the spinal cord largely spares the brain and is not associated with an increased risk of seizures. In addition to being a potentially safer cohort of patients for dalfampridine, TM is a more homogenous disease model in which to test the dalfampridine's mechanism of action.

Transverse myelitis, more correctly identified as monophasic idiopathic transverse myelitis is defined as a single episode of inflammation within the spinal leading to disability at the level of the lesion and below. The majority of TM lesions strike the thoracic cord causing impairments in lower extremities and the single lesion is the cause of all of their symptoms. The goal of using dalfampridine in these patients is to amplify axonal conductance across this single lesion that would manifest in improved neurologic function involving the lower extremities including gait. This is the most straightforward proof of concept experimental model proving the mechanism of action of dalfampridine. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01446575
Study type Interventional
Source Johns Hopkins University
Contact
Status Terminated
Phase Phase 4
Start date July 2012
Completion date November 2013

See also
  Status Clinical Trial Phase
Recruiting NCT03887273 - Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Phase 1/Phase 2
Recruiting NCT04721717 - AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Recruiting NCT05630313 - Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT06147258 - The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury N/A
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Recruiting NCT01623076 - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Active, not recruiting NCT04564495 - Home Based Tele-exercise for People With Chronic Neurological Impairments N/A
Enrolling by invitation NCT00704626 - Serum Auto-Antibodies in Neurological Diseases
Completed NCT02341950 - Clinical Trial of a Serious Game for Individuals With SCI/D N/A
Completed NCT02166346 - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Phase 2
Completed NCT00179478 - Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Phase 4
Completed NCT03336762 - Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis
Recruiting NCT05249595 - Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance N/A
Not yet recruiting NCT06055998 - Frequency ,Etiology and Prognostic Factors of Acute Transverse Myelitis
Enrolling by invitation NCT06163508 - A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
Completed NCT03138421 - Central Pain Study for ABX-1431 Phase 1
Recruiting NCT05017142 - Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)